POSTER: ALL-357 An Economic Model Comparing the Costs Associated with Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Among Patients Treated with Chimeric Antigen Receptor T-Cell Therapies (CAR Ts) for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)